CLOs on the Move

Foghorn Therapeutics

www.foghorntx.com

 
More than 20,000 genes make us human. Genes control critical aspects of health and disease — but what controls our genes? Foghorn® Therapeutics ($FHTX) is developing therapies based on a system that directs which genes our cells express, and when, where, and in what order. By manipulating this system with our unique Gene Traffic Control™ platform, Foghorn will change how genes turn “on” and “off.” Unlike approaches that edit genes, this novel way of thinking will alter what our DNA has in store for us—and rewrite destiny for millions of people living with disease. With Gene Traffic Control™ Foghorn is ...
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.foghorntx.com
  • 500 Technology Square Suite 700
    Cambridge, MA USA 02139
  • Phone: 617.586.3100

Executives

Name Title Contact Details
Michael LaCascia
Chief Legal Officer Profile

Similar Companies

Alliant Management Services

Alliant Management Services is a Louisville, KY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

MEDRAD Interventional/POSSIS

Possis Medical, Inc. is a developer, manufacturer and marketer of medical devices, operating in one business segment.

Simple Contacts

Extend your prescription and reorder lenses in just 5 minutes without the doctor`s visit.

Aribex

Aribex is a Orem, UT-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Cellanyx

Cellanyx has developed proprietary live tumor cell phenotypic biomarker tests to improve cancer risk-stratification and allow informed clinical decision making. The Companys unique approach provides quantitative and actionable information based on analysis of thousands of live tumor cells. The Companys tests employ a microfluidic platform combined with machine vision and machine learning approaches to analyze phenotypic morphological, biochemical and biophysical markers. Cellanyx has demonstrated initial clinical proof-of-concept with its lead phenotypic test in prostate cancer. The initial clinical proof-of-concept study was conducted to demonstrate improved risk stratification in men with low and intermediate Gleason grade (6 and 7) disease and reduce the number of repeat biopsies. Furthermore, analysis of field samples (away from the suspicious core) demonstrated the potential value of Cellanyx phenotypic test as it was able to analyze the tumor microenvironment conditions and predict expected adverse pathology from samples that were not taken from the suspicious core. These new findings from the Cellanyx prostate test are transformative as it will reduce the errors in diagnosing cancers early due to sampling heterogeneity of prostate biopsies.